Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Follow-Up Questions
Who is the CEO of Immuneering Corp?
Dr. Benjamin Zeskind is the President of Immuneering Corp, joining the firm since 2008.
What is the price performance of IMRX stock?
The current price of IMRX is $6.21, it has decreased 2.64% in the last trading day.
What are the primary business themes or industries for Immuneering Corp?
Immuneering Corp belongs to Biotechnology industry and the sector is Health Care
What is Immuneering Corp market cap?
Immuneering Corp's current market cap is $358.1M
Is Immuneering Corp a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Immuneering Corp, including 3 strong buy, 7 buy, 1 hold, 0 sell, and 3 strong sell
